AIFA updates Rybrevant registry timing for carboplatin combinations in EGFR exon 20 lung cancer
Italy's medicines agency has changed the timing of selecting carboplatin-containing combination regimens in the Rybrevant (amivantamab) monitoring registry's drug request form for first-line NSCLC.
The Italian Medicines Agency (AIFA) has updated the monitoring registry for Rybrevant (amivantamab), according to a notice published on 6 November 2026 by its Registry Monitoring Office.
The update covers the registry for one indication: amivantamab combined with carboplatin and pemetrexed as first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) carrying activating EGFR exon 20 insertion mutations.
AIFA says the change is in the drug request (Richiesta Farmaco, RF) form, where the timing for selecting combination regimens containing carboplatin has been updated. The notice gives no further detail on what the new timing is.
The agency also reminded prescribers that prescriptions must follow the eligibility and prescribing-appropriateness criteria set out in the clinical form. That form can be downloaded as a .zip file from the list of active AIFA monitoring registries, which is reachable through the related links on the notice page.
As general context, AIFA monitoring registries are web-based tools through which prescribing centres request and track treatment with certain medicines, and they are linked to reimbursed access in Italy.
What it means for your team
- Prescribing centres and registry users handling amivantamab requests should review the updated RF form, particularly the point at which carboplatin-containing regimens are selected.
- Teams should download the current clinical form from AIFA's list of active registries to confirm the eligibility and appropriateness criteria in force.
- Market-access teams should note the notice does not describe the practical effect of the timing change, so any workflow impact should be checked directly in the registry.
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial